Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control

Volumn 4, Issue 1, 2015, Pages

  Harris, Patrick N ^a,b,c   Yin, Mo ^b,c   Jureen, Roland ^b,c   Chew, Jonathan ^d   Ali, Jaminah ^b   Paynter, Stuart ^e   Paterson, David L ^a   Tambyah, Paul A ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carbapenem; Enterobacteriaceae; Extended spectrum lactamase; Piperacillin tazobactam

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84938483696     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/s13756-015-0055-6     Document Type: Article

References (35)

1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-66. doi:10.1016/S1473-3099(08)70041-0.
2. Medeiros AA. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum beta-lactamases have arrived in North America. Ann Intern Med. 1993;119(5):428-30.
3. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56(5):641-8. doi:10.1093/cid/cis942.
4. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682-90. doi:10.1086/604713.
5. Stuart RL, Kotsanas D, Webb B, Vandergraaf S, Gillespie EE, Hogg GG, et al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust. 2011;195(9):530-3.
6. Rooney PJ, O'Leary MC, Loughrey AC, McCalmont M, Smyth B, Donaghy P, et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother. 2009;64(3):635-41. doi:10.1093/jac/dkp220.
7. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62(4):280-91.
8. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The Global Spread of Healthcare-Associated Multidrug-Resistant Bacteria: A Perspective From Asia. Clin Infect Dis. 2013;56(9):1310-8.
9. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH, et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010;54(3):1173-8. doi:10.1128/AAC.01076-09.
10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
11. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008;9(1):23-37. doi:10.1517/14656566.9.1.23.
12. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131-3. doi:10.1128/AAC.00607-13.
13. Chang H-J, Hsu P-C, Yang C-C, Kuo A-J, Chia J-H, Wu T-L, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteraemia: A matched case-control study. J Microbiol Immunol Infect. 2011;44(2):125-30.
14. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57(3):1488-95.
15. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263-72.
16. Glasner C, Albiger B, Buist G, Tambic Andrasevic A, Canton R, Carmeli Y et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro surveill. 2013;18(28). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20525.
17. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18(5):439-48.
18. Perez F, Bonomo RA. Can we really use beta-lactam/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria? Clin Infect Dis. 2012;54(2):175-7.
19. Harris PN, Tambyah PA, Paterson DL. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15(4):475-85.
20. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167-74.
21. Retamar P, Lopez-Cerero L, Muniain MA, Pascual A, Rodriguez-Bano J, Group E-RG. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013;57(7):3402-4. doi:10.1128/AAC.00135-13.
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9. doi:10.1016/j.jclinepi.2007.11.008.
23. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters version 5.0. 2015. www.eucast.org .
24. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791-7.
25. Charlson M, Szatrowski P, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-51.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29.
27. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140(1):26-32.
28. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793-803.
29. Pitout JD, Le PG, Moore KL, Church DL, Gregson DB. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and. Infectious Diseases. 2010;16(2):165-70. doi:10.1111/j.1469-0691.2009.02756.x.
30. Sheng W-H, Badal RE, Hsueh P-R. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among enterobacteriaceae isolates causing intra-abdominal infections in the Asia-pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981-8. doi:10.1128/AAC.00971-12.
31. Koh TH. Gram-negative resistance in Singapore: a historical perspective. Ann Acad Med Singap. 2008;37(10):847-54.
32. Koh TH, Cao D, Shan QY, Bacon A, Hsu LY, Ooi EE. Acquired carbapenemases in enterobactericeae in Singapore, 1996-2012. Pathology. 2013;45(6):600-3. doi:10.1097/PAT.0b013e3283650b1e.
33. Gutiérrez-Gutiérrez B, Salamanca E, Pérez-Galera S, Bonomo R, Carmeli Y, Paterson D et al. Assessment of betalactam/beta-lactamase inhibitor combinations for the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: The INCREMENT Project. Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract K-1041). Washington, DC: American Society for Microbiology, 2014.
34. Deresinski S. In the literature. Piperacillin-tazobactam and extended-spectrum beta-lactamase-producing Escherichia coli. Clin Infect Dis. 2013;57(10):3-4.
35. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015. doi:10.1093/cid/civ003.